Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell
lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment …

ABSTRACT INTRODUCTION For patients with advanced epidermal growth factor receptor
(EGFR)-mutated non-small cell lung cancer (NSCLC) who progress on first-line osimertinib …

Highlights•Acquired resistance mechanisms to osimertinib can be EGFR dependent or
independent.•First-and fourth-generation EGFR-TKIs are able to overcome EGFR …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S165-S170 tlcr. amegroups. com the mechanisms of acquired resistance to EGFR …

Background Response rates of epidermal growth factor receptor (EGFR)-mutated advanced
non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) …

The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has
improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung …

Background Osimertinib is now a standard treatment for patients with previously untreated
EGFR-mutated advanced non–small cell lung cancer (NSCLC). We here investigated …

Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …

Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Understanding …

Background The third-generation epidermal growth factor receptor (EGFR)–tyrosine kinase
inhibitor (TKI) osimertinib has become the standard treatment for patients with pretreated …